Roche Receives FDA Approval for Tecentriq Label Expansion in Lung Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 06 2025
0mins
Source: NASDAQ.COM
FDA Approval of Tecentriq Expansion: Roche's immunotherapy drug Tecentriq has received FDA approval for label expansion, allowing its use in combination with Jazz Pharmaceuticals' Zepzelca for the maintenance treatment of extensive-stage small cell lung cancer (ES-SCLC) after first-line therapy. This marks the first combination therapy approved for this indication.
Roche's Financial Performance and Acquisitions: Roche's shares have increased by 32.5% year-to-date, driven by strong sales in its Pharmaceuticals Division, which grew 10% in the first half of 2025. The company also announced plans to acquire 89bio, Inc. for $3.5 billion to enhance its portfolio in cardiovascular and metabolic diseases, despite facing some pipeline setbacks.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
